Context: Although a-glucosidase inhibitors (AGIs) have been shown to reduce the risk of myocardial infarction in patients with impaired glucose tolerance, the cardiovascular benefits of AGIs in those with type 2 diabetes (T2D) remains unclear.
A lthough diabetes is a well-known risk factor for adverse cardiovascular events and microvascular diseases (1, 2) , aggressive strategies for glucose control alone have met neither the clinical expectations of improved survival nor a reduced number of atherosclerotic events (3) . Despite the limited evidence of cardiovascular benefit in the reported data (4), metformin has usually been recommended as the first-line pharmacological therapy for type 2 diabetes (T2D) because it has been shown to decrease the risk of diabetes-related endpoints in patients who are overweight with T2D (5) . When patients require an add-on remedy, other oral hypoglycemic agents (OHAs) would be used to achieve the glycated Hb (HbA1c) target. However, these can be accompanied by unfavorable side effects that offset the potential clinical benefits (6) (7) (8) . Although sulfonylureas can carry detrimental risks of mortality (9) in patients with T2D, cardiovascular outcome studies have shown that dipeptidyl peptidase-4 inhibitors neither increase nor reduce overall cardiovascular events (10, 11) . Saxagliptin has been shown to increase the risk of heart failure, and such an adverse effect cannot be excluded for alogliptin (10, 12) . Recently, both glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 inhibitors have been demonstrated to decrease the adverse cardiovascular events in treating high-risk patients with T2D (13) (14) (15) . Given the inconvenience of injection and high costs, the early use and generalizability of either GLP-1 receptor agonists or sodium-glucose cotransporter 2 inhibitors remains debatable. Although most patients with T2D require additional OHAs to improve glycemic control (16) , the choice of a good second-line drug is especially critical for cardiovascular disease prevention.
Acarbose, an a-glucosidase inhibitor (AGI) available for .20 years, delays the absorption of carbohydrates, reducing postprandial hyperglycemia. Acarbose might represent a suitable drug of choice for Asian populations, who usually consider rice (a source of carbohydrates) a staple food (17) . In addition, the remaining unabsorbed nutrients might increase L-cell activity and thereby facilitate incretin secretion for improved glycemic control (18) . In the STOP-NIDDM study (study to prevent non-insulin-dependent diabetes mellitus), acarbose was not only successful in the prevention of diabetes development in patients with impaired glucose tolerance (IGT) but was also able to significantly reduce the number of cardiovascular events (19) . However, the efficacy and safety of acarbose in patients with T2D require further elucidation. In the present study, we compared the clinical effects of acarbose and sulfonylureas, the most frequently used add-on OHA in many countries, in reducing the number of cardiovascular events in patients with T2D treated with metformin.
Materials and Methods

Selection criteria
To improve the quality of diabetes care, the Taiwan National Health Insurance Administration launched the Diabetes Pay-for-Performance program in 2001 to encourage a multidisciplinary approach to diabetes management (20) . The electronic archives of the Diabetes Pay-for-Performance program, including patient demographic data, prescribed medications, health care usage, and annual HbA1c levels, were merged with the National Health Insurance Research Dataset (21) . Patients aged $20 years with acarbose or sulfonylureas as the sole choice of OHA second to metformin treatment were included in the present study (n = 417,240). Of these patients, 206,791 were excluded because metformin had been discontinued or had not been prescribed within 90 days before the first add-on remedy from 2004 to 2015. Finally, we included 14,306 and 196,143 patients treated with metformin plus acarbose or sulfonylureas as their second-line OHA, respectively. The propensity scorematched selection of patients included in the present study are listed in Table 1 .
The index date indicates when acarbose or sulfonylureas was first prescribed. The length of exposure to acarbose or sulfonylurea (including gliclazide, glipizide, gliquidone, glibornuride, glyburide, and glimepiride) treatment with metformin therapy was calculated as the time from the index date to the occurrence of the investigated outcomes or to the final prescription of acarbose or sulfonylureas during the observation period. An interval of .90 days between prescription refills was considered to indicate therapy discontinuation. Patients were censored from the study when metformin, acarbose, or sulfonylurea treatment was discontinued, when a switch in the treatment occurred between the use of acarbose and sulfonylureas, or when patients withdrew from the National Health Insurance program. Patient follow-up examinations continued until either the investigated outcomes or the end of the study (31 December 2015) was reached, whichever occurred first.
Outcomes
The primary outcomes of the present study were as follows: (1) all-cause mortality and hospitalizations for (2) ischemic stroke [International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 433.x, 434.x, or 436]; (3) myocardial infarction (MI; ICD-9-CM code 410.x); (4) major atherosclerotic events (a composite of hospitalizations for ischemic stroke and MI); and (5) heart failure (HF; ICD-9-CM code, 428.x). The secondary outcome of the present study was hospitalization for hypoglycemia (ICD-9-CM code 251.0x, 251.1x, or 251.2x). All-cause mortality was confirmed by linking our study data set with the national electronic death registry.
Definitions of covariates
All covariates controlled in the present study were defined according to the ICD-9-CM code (two or more diagnoses for outpatients or one or more diagnosis during hospitalization) within 1 year before the index date. The covariates included hypertension (code 401), dyslipidemia (code 272), atrial fibrillation (code 427.3), cancer (codes 140 to 199), liver disease (codes 070, 570 to 573), renal disease (codes 403 to 404, 580 to 586), stroke (codes 430 to 433 and 435), coronary heart disease (codes 410 to 414 and 429.2), peripheral vascular disease (codes 440 to 447), peptic ulcer (codes 531 to 533), valvular heart disease (codes 394 to 396, 424, and 746), and autoimmune disease (code 279.4). In addition, the Charlson comorbidity index and diabetes complication severity index (DCSI) were included in the multivariable models (22) .
Statistical analysis
Comparisons between acarbose and sulfonylureas treatments were made using the unpaired Student t test and the x 2 test for parametric continuous and categorical data, respectively. To minimize the effects caused by confounding factors, we conducted a propensity score-matched analysis. We calculated the propensity score for the likelihood of using acarbose via multivariable logistic regression analysis, conditional on the baseline covariates listed in Table 1 . Hazard ratios (HRs) and 95% CIs determined from the Cox proportional hazards model were used to evaluate the additive effect of acarbose or sulfonylureas on the investigated outcomes. The survival time was calculated as the interval from the first day of the use of acarbose or sulfonylureas to the development of the investigated outcomes or the end of the study (31 December 2015) . The proportional hazards assumption (constant HR over time) was evaluated by comparing the estimated log-log survival curves for all time-independent covariates. We conducted a sensitivity analysis using the intention-to-treat principle such that all patients were followed up until the development of the investigated outcomes or the end of the study. All statistical analyses were performed using the Statistical Package for SAS, version 9.4 (SAS Institute, Inc., Cary, NC), and two-sided P , 0.05 was considered statistically significant.
Results
Before propensity score matching (Table 1) , the patients treated with acarbose were older, predominantly female, and exhibited more comorbidities, higher DCSI scores, and greater percentage of antihypertensive medication use. After propensity score matching, most of the baseline characteristics did not differ substantially between the two groups, except for the DCSI score and some medications ( Table 1) .
The baseline HbA1c levels were 7.98% (63.78 mmol/mol) and 7.94% (63.34 mmol/mol) in patients treated with sulfonylureas and acarbose, respectively. The achievement of glycemic control was comparable between the groups during the observation period (data not shown). During the 11-year follow-up period, 50 patients treated with sulfonylureas and 24 patients treated with acarbose as second-line treatment of T2D died. Compared with patients treated with sulfonylurea, those treated with acarbose exhibited significantly lower risks for ischemic stroke (HR, 0.68; 95% CI, 0.49 to 0.94) and atherosclerotic (HR, 0.69; 95% CI, 0.52 to 0.91) and hypoglycemic (HR, 0.23; 95% CI, 0.08 to 0.71) events. However, the risks for all-cause mortality (HR, 0.77; 95% CI, 0.46 to 1.27) and hospitalizations for MI (HR, 0.66; 95% CI, 0.40 to 1.11) and HF (HR, 0.92; 95% CI, 0.65 to 1.31) were comparable between the two groups (Tables 2 and 3 ; Fig. 1 ).
When conducting an intention-to-treat analysis, patients treated with acarbose demonstrated favorable cardiovascular outcomes, including a reduced risk for ischemic stroke (HR, 0.80; 95% CI, 0.70 to 0.93), MI (HR, 0.74; 95% CI, 0.59 to 0.94), atherosclerotic events (HR, 0.80; 95% CI, 0.71 to 0.91), and hospitalization for hypoglycemia (HR, 0.45; 95% CI, 0.27 to 0.77; Table 3 ).
Discussion
The results of the present study have clearly shown that acarbose, as an add-on therapy to metformin, was associated with better cardiovascular outcomes in the reduction of ischemic stroke and atherosclerotic events compared with sulfonylureas. In addition, acarbose was associated with fewer hypoglycemic events than was sulfonylurea. The results of the present study might support acarbose for the treatment of patients with T2D in whom metformin has failed to achieve the therapeutic goal of glycemic control.
Acarbose competitively inhibits a-glucosidase, which is responsible for the hydrolysis of oligo-saccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the brush border of the small intestine (17) . The inhibition of a-glucosidase might delay the digestion of complex carbohydrates and retard the absorption of glucose, and, consequently, improve postprandial glucose control. Acarbose would also increase the serum levels of GLP-1 by regulating the reabsorption of bile acid or stimulating L cells directly with the unabsorbed carbohydrate to achieve glycemic control (18, 23) . The efficacy of AGIs has been comparable to other OHAs and could potentially represent a better option for glycemic control in Asian populations, for whom rice is considered a staple food (24) . Compelling evidence has shown that HbA1c is more related to the postprandial glucose levels than to the fasting glucose levels, with former contributing to an approximate threefold increase in the risk of developing coronary heart disease or other major adverse cardiovascular events (25, 26) . Data from the Collaborative Analysis of Diagnostic Criteria in Europe and the San Luigi Gonzaga study have similarly reported postprandial blood glucose as an independent risk factor for cardiovascular events and mortality in patients with T2D (27, 28) , although the underlying mechanism is still obscure, and we do not yet know whether this epidemiological association is a causal relationship.
In addition to improving the vasomotion in patients with T2D (29, 30) , acarbose is beneficial in delaying the progression of the carotid intima-media thickness in patients with both coronary artery disease and IGT or mild diabetes (31) . The STOP-NIDDM trial further demonstrated a reduction in the incidence of overt diabetes of 36% with 3 years of treatment with acarbose in patients with IGT (19) . More importantly, acarbose reduced the risk of MI by 91%, cardiovascular events by 49%, and incident hypertension by 34% (32). However, acarbose in the ACE (acarbose cardiovascular evaluation) trial failed to reduce the incidence of cardiovascular events during a 5-year treatment period (33) , resulting in doubt regarding the effects of acarbose on secondary cardiovascular prevention for patients with IGT and coronary heart disease. Although the ACE study compared acarbose with placebo in the treatment of patients with IGT, the results from the present study might complete the gap. When adequate glycemic control with metformin in patients with T2D failed, acarbose outperformed sulfonylurea as the second-line OHA for preventing atherosclerotic events. Hanefeld et al. (34) conducted the MeRia study (metaanalysis of risk improvement under acarbose), a metaanalysis comprising seven randomized acarbose studies, and demonstrated that acarbose treatment, compared with placebo, significantly reduced the risk of any cardiovascular event by 35% and that of MI alone by 64%. In contrast, with the exception of improved glycemic control, a recent Cochrane systemic review and metaanalysis did not reveal any prognostic benefit with acarbose treatment of T2D (35, 36) .
Given the limited population of patients with T2D (n = 2180) in the MeRia study and restricted follow-up duration in the Cochrane studies (34) (35) (36) , the long-term efficacy and safety of acarbose in treating patients with T2D remain unknown. In the MeRia study, patients in both acarbose and placebo arms had baseline HbA1c levels of 8.5% (34), a level commonly requiring additional treatment with metformin. The present study with similar glycemic control in both comparison groups has indicated that acarbose has clinical benefits compared with sulfonylurea.
In the present nationwide retrospective study, we showed that the addition of acarbose to metformin treatment of T2D can result in a reduction in atherosclerotic events and ischemic stroke. Our study presents robust, real-world evidence of acarbose as a second-line OHA for the reduction of atherosclerotic cardiovascular Events and person-y calculations were determined using data from propensity score-matched subjects. a Major atherosclerotic events included MI and ischemic stroke.
events. Patients with diabetes have a propensity to develop HF (32, 37) , which has been associated with high mortality rates (38) . In contrast to other OHAs such as dipeptidyl peptidase-4 inhibitors or thiazolidinedione, which have been associated with an increased risk of HF (11, 39) , the present study has demonstrated that the use of acarbose in addition to T2D treatment with metformin is less likely to result in HF. The present study revealed a 77% reduction in hypoglycemic events with the addition of acarbose vs sulfonylureas to metformin treatment of T2D. Acarbose has been associated with a lower incidence of hypoglycemia and an absence of weight gain compared with other OHAs, such as sulfonylureas, meglitinides, thiazolidinediones, and insulin (40) . A lower rate of hypoglycemia might contribute to the reduction of cardiovascular events in those with T2D (7, 41) . The results from the present study support the observation by Chang et al. (42) that acarbose treatment is associated with a lower risk of acute MI. Our results further suggest the cardiovascular benefits of acarbose, which occur independently of glucose control.
Study limitations
The present study had some limitations. (1) Individual socioeconomic status, educational qualifications, and behavioral characteristics (e.g., smoking status, physical activity, and body mass index) were not available in our data set, which could have had an effect on the results. Despite the possibility of a nondifferential information bias, the present study showed substantial clinical advantages with the use of acarbose compared with sulfonylurea as an add-on to metformin treatment. Moreover, propensity score matching was conducted to minimize the selection bias. Although some residual differences were still observed between the matching cohort for dyslipidemia, cancer, the use of a-blockers, and the use of potassium-sparing diuretics, these would be unlikely to explain the results. In addition, we found small differences in the DCSI score; however, this would have actually favored the sulfonylureas arm from a cardiovascular outcome viewpoint. (2) We acknowledge that ascertainment of the covariates used in the present study with ICD-9-CM coding is sometimes inaccurate; however, we used relatively stricter criteria (two or more diagnoses for outpatients or one or more for hospitalization within 1 year before the index event) to define all covariates. We believed cases of an incorrect diagnosis could be minimized. (3) The study subjects were selected across an 11-year period (2004 to 2015) . However, the mean follow-up time was only 1.29 6 1.84 years. The reasons for withdrawal from each arm are unclear; however, we believe that intolerability of the side effects of acarbose, such as diarrhea and flatulence, were the primary reasons for drug termination or switch (17) . The ACE trial also encountered the problem of poor adherence to acarbose treatment (33) . The high frequency of drug choice changes reflects the use of OHAs in the real world. To avoid such confounding effects, we censored study subjects when the OHA prescription was changed, which resulted in the loss of subjects at risk throughout the prolonged follow-up period. Nevertheless, the results were similar even when we changed our analysis strategy to use the intention-to-treat principle to conserve the patient population pool (Table 3) . Similar results were observed by Chang et al. (42) in their intention-to-treat study, in which they showed a reduction in the risk of MI in patients with T2D treated with AGI and metformin. (4) Owing to the multiple models analyzed in the present study, the probability of observing substantial results due to chance could have been increased. To avoid All models were conducted using the propensity score-matched subjects. a Multivariable models were adjusted for all covariates listed in Table 1 .
b In the as-treated approach, patients were censored when metformin, acarbose, or sulfonylureas was discontinued, acarbose or sulfonylurea was switched to the other treatment, or patients withdrew from the National Health Research Institutes program. c In the intention-to-treat approach, all patients were followed up until the investigated outcomes or the end of the study.
d Major atherosclerotic events included MI and ischemic stroke.
overinterpreting the results, we used a Bonferroni correction to set a lower statistically significant level. Because we tested six hypotheses (i.e., all-cause death, major atherosclerotic events, hospitalized MI, ischemic stroke, heart failure, and hypoglycemia) in the present study, we divided the predetermined statistically significant level of 0.05 by 12 (both as-treated and intentionto-treat models for each of the six hypotheses) to obtain a corrected statistically significant level at 0.004. Using this corrected cutoff to assess the statistical significance for the results shown in Table 3 and Fig. 1 , all interpretations remain unchanged, except for the benefit of hospitalized MI (P = 0.0134 becomes insignificant). Therefore, we need to be more conservative regarding the beneficial effect of acarbose on reducing hospitalized MI. (5) Because the study population included Taiwanese patients with T2D only, these results might not be generalizable to other populations with different dietary behaviors.
Clinical implications
In the present nationwide retrospective cohort study, we showed that the addition of acarbose to metformin treatment of T2D can result in a reduction in atherosclerotic events and ischemic stroke. Our study presents robust, real-world evidence of acarbose as a second-line OHA for the reduction of atherosclerotic cardiovascular events, especially in an Asian population.
Conclusion
The use of acarbose as an add-on to metformin treatment reduced the risk of ischemic stroke and atherosclerotic events more effectively than did the use of sulfonylureas. In addition, acarbose was associated with a greater reduction in the risk of hypoglycemia development compared with sulfonylureas. Our study has demonstrated the potential of acarbose to be incorporated into the treatment strategies for T2D in patients with a propensity to develop adverse cardiovascular events and HF.
